To investigate whether CDK1 can be combined with traditional chemotherapy drugs to treat DNMT3A related AML, we conducted pharmaceutical experiments by combining CGP or FLA with the chemotherapy drugs cytarabine (Ara-C), doxorubicin (Dox), or homoharringtonine (HHT). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.